Journal article
Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men
IM Poynten, SN Tabrizi, F Jin, DJ Templeton, DA Machalek, A Cornall, S Phillips, CK Fairley, SM Garland, C Law, A Carr, RJ Hillman, AE Grulich
Papillomavirus Research | ELSEVIER SCIENCE BV | Published : 2017
Abstract
Objective HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM. Methods The Study of the Prevention of Anal Cancer (SPANC) is an ongoing, prospective cohort study of HIV-positive and HIV-negative Australian GBM. Participants completed questionnaires and underwent an anal swab for HPV genotyping using Roche Linear Array. We analysed baseline data from SPANC by HPV type, mean number of types, stratified by age and HIV status. Results Anal HPV results from 606 (98.2%) of 617 participants (median age 49 years, 35.7% HIV-positiv..
View full abstractGrants
Awarded by Bristol-Myers Squibb
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council Program Grant (Sexually transmitted infections: Causes, consequences and interventions Grant #568971); and a Cancer Council New South Wales Strategic Research Partnership Program Grant (Preventing morbidity and mortality from anal cancer Grant #13-11). Cytological testing materials were provided by Hologic (Australia) Pty Ltd. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales and funded by the Australian Government of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government.